mRNA-based vaccines

#Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines #Rare disease #Rare Disease Day #Thermo Fisher Scientific

Unlocking the potential of mRNA for the future treatment of rare diseases 

mRNA technology helped us to vaccinate the world against SARS-CoV-2. As we turn our focus to new potential applications and disease areas for the platform, scientists and companies must consider the potential life-saving impact on rare, inherited diseases, says Archana Gupta, PhD, staff scientist in genetic sciences at Thermo Fisher… Read More

#Exclusive Content #Opinion

#Funding #Immunology / Virology & Vaccines #Investment #mRNA #mRNA-based vaccines

Funding injection for Strep A vaccine research

A research effort to develop an mRNA vaccine against Group A Streptococcus (Strep A) has secured almost $8 million in funding.  The Leducq Foundation has announced support for the University of Queensland-led project that could reduce Strep A infections, which cause more than 500,000 deaths a year… Read More

#News

Vaccine production
#BioNTech #Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #Moderna #mRNA #mRNA-based vaccines #Personalised medicine #UK government

New UK partnership to accelerate mRNA research

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines.  The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines.  Professor Uğur Şahin, Chief Executive… Read More

#Business & Investment #Cancer Research #News #Trending News

#Biologics / Biotechnology #Cell and gene therapy #Covid-19 #Drug discovery #mRNA-based vaccines #Plant-based #Synthetic biology #Ukraine

DDW’s best of 2022: What were your top reads?

2022 was a complicated year. Global challenges like the Ukraine war and the continued impact of Covid-19 have been felt across the world. And yet it was also a year of incredible innovation in drug discovery, with the potential of new biotechnology beginning to be revealed. Our top 10 most… Read More

#Editor's Choice #Exclusive Content #News

#Cancer research #Immunology / Virology & Vaccines #Melanoma #Merck #Moderna #mRNA #mRNA-based vaccines

mRNA cancer vaccine meets primary efficacy endpoint

Personalised mRNA vaccine mRNA-4157/V940 has demonstrated a clinically meaningful improvement in patients with late-stage melanoma.  The vaccine, in combination with Keytruda, met its primary endpoint of recurrence-free survival (RFS) for the adjuvant treatment of patients with stage III/IV melanoma following complete resection.  Adjuvant treatment with… Read More

#Cancer Research #News

HIV vaccine
#Antibodies #HIV #mRNA-based vaccines #Phase I trial

Encouraging trial findings renew hope for HIV vaccine

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial.  In a paper published in Science, the researchers reveal critical new insights… Read More

#News #Trending News

Cell and gene therapy
#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Webinar: How to resolve barriers to CGT discovery

Stream this free webinar, hosted by DDW and supported by Catalent, Early phase support for plasmid DNA supply helps secure future manufacturing for advanced therapies. The webinar was presented by Matthias Craig, Senior Manager Product Development, Catalent. One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production… Read More

#News

#Cancer research #Cancer vaccine #Immuno-oncology #Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines

Merck and Moderna to jointly develop personalised cancer vaccine 

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna.   mRNA-4157/V940 is currently being evaluated in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk… Read More

#Cancer Research #News

Cell and gene therapy
#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Webinar: Overcome barriers to CGT innovation

Watch this free webinar, hosted by DDW and supported by Catalent, which will be presented by Matthias Craig, Senior Manager Product Development, Catalent. One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based… Read More

#News

#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Exclusive webinar: How to remove the barriers to CGT innovation

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene therapies that require pDNA as a starting material.  Watch this free webinar – Early phase support for plasmid DNA supply… Read More

#News

Cell and gene therapy
#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Secure future manufacturing for advanced therapies

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene therapies that require pDNA as a starting material.  Watch this free webinar – Early phase support for plasmid DNA supply… Read More

#News

Cell and gene therapy
#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Webinar: Optimise plasmid production process and supply

This on-demand webinar, hosted by DDW and supported by Catalent, is presented by Matthias Craig, Senior Manager Product Development, Catalent. One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene… Read More

#News

#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Webinar addresses CGT challenges and how to resolve them

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene therapies that require pDNA as a starting material.  Watch this on-demand webinar – Early phase support for plasmid DNA supply… Read More

#News